To view click here

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce key updates on its late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus (“SLE/Lupus”). Highlights Simbec-Orion has been appointed as the Contract Research Organisation (“CRO”), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive due-diligence…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 12.7% shareholding. Within the announcement, Incanthera announces a significant commercial skincare deal with Marionnaud (part of the A.S. Watson…

To view notification form click here

ImmuPharma Plc is pleased to announce that further to the Company’s announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform (“WRAP”), in addition…

To view click here

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce  subscriptions  to raise £1.35 million through the issue of 67,500,000 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 2 pence per Ordinary Share (“Issue Price“) utilising existing authorities to allot shares.…

WRAP Retail Offer for up to £500,000 ImmuPharma Plc is pleased to announce a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise up to £500,000 (the “WRAP Retail Offer”) through the issue of new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”).  Under the WRAP Retail…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £0.8m (30 June 2022:  £1.7m) Research and development expenses of £0.8m (30 June 2022: £1.0m) Administrative expenses…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (“Incanthera”) that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera’s IPO onto the Aquis Exchange, are extended by 12 months.  Key highlights: The Company entered into a Warrant…